Roots Analysis
FEBRUARY 26, 2024
Several Technology Providers, with Proprietary Platforms, have Emerged as Key Enablers Several technology developers have licensed their platforms to other pharmaceutical companies for developing subcutaneous formulation of their approved / pipeline products.
pharmaphorum
SEPTEMBER 23, 2020
Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 27, 2023
Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
Delveinsight
NOVEMBER 29, 2020
Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.
Drug Discovery World
FEBRUARY 5, 2024
Utilising our integrated experimental biology and machine learning platform to realise the power of large-scale, systemic data, we are developing a preclinical pipeline of targeted oncology therapeutics in biomarker-defined settings — reinventing the traditional approach to target and drug discovery.
Pharmaceutical Technology
MAY 31, 2023
Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
Expert insights. Personalized for you.
52 
Let's personalize your content